Pegasys and Copegus Product Information
Safety Information
Contact Us
Site Map
Glossary
Search
PEGASYS® (Peginterferon alfa-2a) for Injection
  • About PEGASYS
  • Taking PEGASYS and COPEGUS
  • Treating Hepatitis C
  • Hepatitis C Basics
  • How do I know if I have Hepatitis C?
  • Living With Hepatitis C
  • PEGASYS for Healthcare Providers
Long term and short term success begins here
  • About PEGASYS + COPEGUS Combination Therapy
  • The Benefits of Treatment
  • PEGASYS Dosing
  • Efficacy Across the Broadest Range of Patients
  • Efficacy for Patients With HCV/HIV Coinfection
  • Efficacy for Patients With Hepatitis B
  • Safety and Tolerability
  • Patient Support
  • Resource Library
  • Healthcare Professional Tools
  • Guide to PEGASYS Prefilled Syringes

Pegassist Support

Because we know that the best treatment plan goes beyond medication.
Hepatitis C Support: PEGASSIST
Resource Library

This section offers helpful sources for healthcare professionals who are seeking further information on hepatitis C and its treatment.

  • Reprints of key articles regarding hepatitis and treatment with PEGASYS
  • Related links and descriptions of relevant outside Web sites
  • A pegylation animation showing how PEGASYS works
  • PEGASYS customizable posters for your practice

Article Reprints

These articles are offered to healthcare professionals to provide current clinical results regarding the treatment of chronic hepatitis C with PEGASYS.

  • Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
  • Hadziyannis SJ et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
  • Lau GKK et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2695.
  • Marcellin P et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:32-43.
  • Torriani FJ et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.

To request the above articles, please call Professional Product Information (PPI) at 1-800-526-6367.


Related Links

The following links related to hepatology, virology, and the treatment of hepatitis C are provided for your convenience. Links to these organizations are provided solely as a service to our Web site visitors. These links do not constitute an endorsement of these organizations or their programs by Roche, and none should be inferred. Roche is not responsible for the content of the individual organization Web pages found at these links. These links will open in a new browser window.

  • American College of Gastroenterology
    http://www.acg.gi.org
    The American College of Gastroenterology was founded in 1932 to advance the study and medical treatment of disorders of the gastrointestinal tract. The college is dedicated to meeting the needs of clinical gastroenterology practitioners. The Web site provides a wide variety of resources including practice guidelines, research grants, general facts about the field, and information for patients.
  • American Liver Foundation
    www.liverfoundation.org
    The American Liver Foundation is a nonprofit health agency that focuses on the prevention and treatment of liver ailments and hepatitis. The Web site offers information for healthcare professionals and patients. Features include updates and clinical trial information, as well as a list of local chapters and support groups.
  • Hepatitis Foundation International
    www.hepfi.org
    This organization seeks to promote worldwide awareness and education about hepatitis. The site includes research articles, a newsletter, and a support-group finder.
  • National Digestive Diseases Information Clearinghouse
    www.niddk.nih.gov/health/digest/nddic.htm
    The National Digestive Diseases Information Clearinghouse (NDDIC) is an information dissemination service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • National Foundation for Infectious Diseases
    http://www.nfid.org/info
    The National Foundation for Infectious Diseases (NFID) is a nonprofit organization dedicated to encouraging and sponsoring public and professional education about infectious diseases, supporting research and training, and aiding in the prevention and treatment of infectious diseases. Site features include a disease library and immunization fact sheets.
  • National Institutes of Health
    http://www.nih.gov
    The National Institutes of Health (NIH) supports clinical research and education on a variety of health issues. The NIH Web site includes hepatitis C publications and management guidelines.
  • Parents of Kids with Infectious Diseases
    http://www.pkids.org
    Parents of Kids with Infectious Diseases (PKIDs) and its Web site support families whose children have been affected by viral hepatitis, HIV/AIDS, or other infectious diseases and educates the public about effective disease-prevention practices. (Note: PEGASYS is not indicated for people under age 18.)
  • US Centers for Disease Control and Prevention—Hepatitis Branch
    http://www.cdc.gov/ncidod/diseases/hepatitis/index.htm
    This site provides information on hepatitis A, B, C, D, and E and a resource center with brochures and slides.
Print this page



THIS SITE INTENDED FOR U.S. AUDIENCES ONLY

For more information about PEGASYS, contact your physician or other healthcare professional.

Photographs used for illustrative purposes.


RocheCopyright © 2002-2008 Hoffmann-La Roche Inc. All rights reserved. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Statement.